A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT07619131

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07619131
  • EU CT 2026-525642-30-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Bulgaria, Canada, Denmark, Germany, Hungary, Israel, Poland, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07619131. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-12 (actual); primary completion 2027-07-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
Condition
Hypercholesterolaemia
Intervention (Drug)
Laroprovstat
Intervention (Drug)
Rosuvastatin 1
Intervention (Drug)
Rosuvastatin 2
Intervention (Drug)
Laroprovstat/Rosuvastatin 1
Intervention (Drug)
Placebo to match rosuvastatin
Intervention (Drug)
Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1
Intervention (Drug)
Laroprovstat/Rosuvastatin 2
Intervention (Drug)
Placebo to match Laroprovstat/Rosuvastatin 2
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07619131
Content hash
c7209b1953001a83af674eddae66568d341b18e6f7f1e579028b0e39b523f84f